Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Merck
Medtronic

Last Updated: August 19, 2022

Investigational Drug Information for CCX168


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug CCX168?

CCX168 is an investigational drug.

There have been 7 clinical trials for CCX168. The most recent clinical trial was a Phase 3 trial, which was initiated on March 15th 2017.

The most common disease conditions in clinical trials are Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, and Atypical Hemolytic Uremic Syndrome. The leading clinical trial sponsors are ChemoCentryx, Mario Negri Institute for Pharmacological Research, and Medpace, Inc.

There are seven US patents protecting this investigational drug and one hundred and seventy-four international patents.

Recent Clinical Trials for CCX168
TitleSponsorPhase
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)ChemoCentryxPhase 2
Controlled Trial Evaluating Avacopan in C3 GlomerulopathyMedpace, Inc.Phase 2
Controlled Trial Evaluating Avacopan in C3 GlomerulopathyChemoCentryxPhase 2

See all CCX168 clinical trials

Clinical Trial Summary for CCX168

Top disease conditions for CCX168
Top clinical trial sponsors for CCX168

See all CCX168 clinical trials

US Patents for CCX168

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CCX168 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
CCX168 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
CCX168 See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
CCX168 See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
CCX168 See Plans and Pricing Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CCX168

Drugname Country Document Number Estimated Expiration Related US Patent
CCX168 Argentina AR077162 2028-12-22 See Plans and Pricing
CCX168 Australia AU2009330194 2028-12-22 See Plans and Pricing
CCX168 Brazil BR112012033075 2028-12-22 See Plans and Pricing
CCX168 Brazil BRPI0923384 2028-12-22 See Plans and Pricing
CCX168 Canada CA2747522 2028-12-22 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.